Send to

Choose Destination
Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Author information

Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address:
Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Janssen Research & Development, LLC, Spring House, Pennsylvania.
Janssen Services, LLC, Horsham, Pennsylvania.
Department of Hepatogastroenterology and Centre D'Investigation Clinique Chu Lille, Université Lille Nord De France, Lille, France; Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Gastroenterology and Hepatology, Universitätsklinik für Innere Medizin III, Vienna, Austria.
Department of Gastroenterology, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
Division of Gastroenterology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon.
Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Department of Internal Medicine, School of Medicine, Keio University, Minato, Tokyo, Japan.
Department of Gastroenterology, University Hospital, Gasthuisberg, Leuven, Belgium.



Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment.


We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6-12; endoscopic subscore ≥ 2; 774 patients in phase 3). Patients were randomly assigned to groups given golimumab doses of 100 mg and then 50 mg (phase 2 only), 200 mg and then 100 mg, or 400 mg and then 200 mg, 2 weeks apart. The phase 3 primary end point was week-6 clinical response. Secondary end points included week-6 clinical remission, mucosal healing, and Inflammatory Bowel Disease Questionnaire (IBDQ) score change.


In phase 2, median changes from baseline in the Mayo score were -1.0, -3.0, -2.0, and -3.0, in the groups given placebo, 100 mg/50 mg, 200/100 mg, and 400/200 mg golimumab, respectively. In phase 3, rates of clinical response at week 6 were 51.0% and 54.9% among patients given 200 mg/100 mg and 400 mg/200 mg golimumab, respectively, vs 30.3% among those given placebo (both, P ≤ .0001). Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both golimumab groups vs the placebo group (P ≤ .0014, all comparisons). Rates of serious adverse events were 6.1% and 3.0%, and rates of serious infection were 1.8% and 0.5%, in the placebo and golimumab groups, respectively. One patient in the 400 mg/200 mg group died as a result of surgical complications of an ischiorectal abscess.


Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. Number: NCT00487539.


AZA; C-reactive protein; CRP; Dose−Response; Human Monoclonal Antibody; IBDQ; Inflammatory Bowel Disease; Inflammatory Bowel Disease Questionnaire; PK; PURSUIT-SC; Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment−Subcutaneous; SC; TNF; TNF Antagonist; UC; azathioprine; pharmacokinetic; subcutaneous; tumor necrosis factor; ulcerative colitis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center